Thomas Andersen

Ph.d.-kandidat

Vitenskapelig artikkel

Vis forfatter(e) (2023). Procollagen type 1 N-terminal propeptide is associated with adverse outcome in acute chest pain of suspected coronary origin. Frontiers in Cardiovascular Medicine.

Vis forfatter(e) (2022). Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine. 1-9.

Vis forfatter(e) (2019). Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial. European Heart Journal: Acute Cardiovascular Care. 313-322.
Vis forfatter(e) (2019). C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology. 2402-2410.

Poster

Vis forfatter(e) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A9149. The novel Wnt-Pathway inhibitor podogan is not associated with all-cause mortality or cardiovascular outcome in patients admitted with suspected acute coronary syndrome. .
Vis forfatter(e) (2021). Circulation 2021 (Nov. 8); 144 (Suppl. 1): A12013. Procollagen type-1 N-terminal propeptide, a collagen synthesis biomarker, is associated with adverse clinical outcome in patients with nsuspected acute coronary syndrome. .